317 related articles for article (PubMed ID: 29912623)
1. Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Chen K; Zhuo T; Wang J; Mei Q
Metab Syndr Relat Disord; 2018 Sep; 16(7):336-341. PubMed ID: 29912623
[TBL] [Abstract][Full Text] [Related]
2. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
Fang H; Xu F; Du J; Liang L; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
J Diabetes Investig; 2020 Jul; 11(4):896-905. PubMed ID: 32020731
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
4. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
Leibowitz G; Cahn A; Bhatt DL; Hirshberg B; Mosenzon O; Wei C; Jermendy G; Sheu WH; Sendon JL; Im K; Braunwald E; Scirica BM; Raz I
Diabetes Obes Metab; 2015 May; 17(5):487-94. PubMed ID: 25656169
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
10. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Poucher SM; Cheetham S; Francis J; Zinker B; Kirby M; Vickers SP
Diabetes Obes Metab; 2012 Oct; 14(10):918-26. PubMed ID: 22564773
[TBL] [Abstract][Full Text] [Related]
11. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
[TBL] [Abstract][Full Text] [Related]
12. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V; Zhu T; Karyekar C; Hirshberg B
Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
14. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
16. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Tao T; Wu P; Wang Y; Liu W
BMC Endocr Disord; 2018 Feb; 18(1):14. PubMed ID: 29482528
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
[TBL] [Abstract][Full Text] [Related]
18. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
Chen Y; Liu X; Li Q; Ma J; Lv X; Guo L; Wang C; Shi Y; Li Y; Johnsson E; Wang M; Zhao J; Ji L
Diabetes Obes Metab; 2018 Apr; 20(4):1044-1049. PubMed ID: 29144061
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Dou J; Ma J; Liu J; Wang C; Johnsson E; Yao H; Zhao J; Pan C
Diabetes Obes Metab; 2018 Mar; 20(3):590-598. PubMed ID: 28926170
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson JG; Hellqvist Å; Gause-Nilsson I
Int J Clin Pract; 2013 Apr; 67(4):307-16. PubMed ID: 23638466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
